Corgenix Medical Corp’s second generation Hyaluronic Acid (HA) Immmunoturbidimetric Test Kit for use on automated chemistry analyzers has received CE marking for commercialization in Europe. The new product is the second Corgenix product for measuring blood levels of hyaluronic acid to assess the degree of liver fibrosis and cirrhosis in chronic liver disease.
“The CE marking of our automated HA product reaffirms our market leadership position in non-invasive biomarkers for assessing chronic liver disease and allows us to commercialize the product in Europe through our distribution partner ELITech,” said Corgenix president and CEO Douglass Simpson. “We have a very active development program with ELITech and over the next few years will be bringing additional new and exciting products to the world markets.”
In 2010, Corgenix and ELITech entered into the joint product development agreement, a strategic alliance to co-develop new diagnostic tests. The automated HA product was the first product released as a result of that collaboration. It is now available worldwide, including Europe, through ELITech; in the US it will be available for research purposes only through Corgenix.
It is part of Corgenix’s long-term plan to seek FDA clearance in the US.
Source: Corgenix Medical Corp
